FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

TATEMENT	<b>OF CHANGES</b>	<b>IN BENEFICIAL</b>	<b>OWNERSHIP</b>

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average bu	rden									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  EDWARDS MARK G				<u>A</u> (	2. Issuer Name <b>and</b> Ticker or Trading Symbol ACELRX PHARMACEUTICALS INC ACRX ]									ck all applic Directo	able) r	) Pers	on(s) to Issu	ner	
(Last) (First) (Middle) C/O ACELRX PHARMACEUTICALS, INC. 351 GALVESTON DRIVE					3. Date of Earliest Transaction (Month/Day/Year) 06/25/2019										(give title		Other (s below)	респу	
(Street) REDWO CITY (City)	C		94063 (Zip)		-   4. l	f Ame	endment,	Date	of Original I	=iled	(Month/Da	uy/Year)		6. Ind Line) X	Form fi	led by One led by More	Repo	(Check Apporting Person	
(City)	(3		,	a Doris	vativ		ouritio		auirad	Dici	ancod o	f or Br	nofi	cially	Owned				
1. Title of Security (Instr. 3)  2. Trans: Date			saction			quired, Disposed of, or Benefi  3. Transaction Code (Instr. 8)  4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			) or 5. Amou 4 and Securitie Benefici		nt of 6. C es For ally (D) Following (I) (		m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
									Code	v	Amount	(A) ( (D)	or P	rice	Transact (Instr. 3	ion(s)			,
Common Stock <sup>(1)</sup> 06/25				5/201	/2019		A		3,750	750 <sup>(2)</sup> A S		\$0.00	203	203,750		D			
		-	Гable II -						uired, D s, option						Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,		saction of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		tive ties ed sed	6. Date Exe Expiration (Month/Day		7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)			b. Price of Derivative Security Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
					Code	v	(A)		Date Exercisable		Expiration Date	Title	or	ount nber ires					
Stock Option (Right to Buy)	\$2.19	06/25/2019			A		7,500		07/25/2019 <sup>0</sup>	(3)	06/25/2029	Common Stock	7,5	500	\$0.00	7,500		D	

## **Explanation of Responses:**

- 1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- 2. The restricted stock units shall vest in two equal consecutive annual installments on June 25, 2020 and June 25, 2021, subject to Reporting Person's continuous service to the Company.
- 3. The shares subject to the option vest as follows: 1/24th of the shares subject to the option vest in equal monthly installments over 24 months, subject to Reporting Person's continuous service to the Company.

## Remarks:

/s/ Martha Adler, Attorney-In-

06/25/2019

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.